Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Voronoi (310210 KS)
Watchlist
12
Analysis
Health Care
•
South Korea
Voronoi, Inc. operates as a drugs development company. The Company develops and manufactures kinase inhibitor and other new drugs. Voronoi provides services in Korea.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Lunit
•
03 Sep 2023 22:10
KOSDAQ150 Index Rebalance Preview: Strong Momentum Leads to Outperformance
There could be 14 changes for the KOSDAQ150 in Dec. There could be changes even prior to Dec due to delistings/section transfers. Momentum in Korea...
Brian Freitas
Follow
556 Views
Share
bullish
•
HDFC Bank
•
01 Jul 2023 22:09
Index Rebalance & ETF Flow Recap: KQ150, LQ45, PCOMP, HDFC/HDFCB, Delta Electronics, Redox IPO, AMFI
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
Brian Freitas
Follow
487 Views
Share
bearish
•
Bionote
•
31 May 2023 09:02
End of Mandatory Lock-Up Periods for 45 Companies in Korea in June 2023
We discuss the end of the mandatory lock-up periods for 45 stocks in Korea in June 2023, among which 6 are in KOSPI and 39 are in KOSDAQ.
Douglas Kim
Follow
408 Views
Share
bearish
•
Cross Asset Strategy
•
31 Aug 2022 06:24
End of Mandatory Lock-Up Periods for 40 Companies in Korea in September 2022
We discuss end of the mandatory lock-up periods for 40 stocks in Korea in September 2022. These 40 stocks on average could be subject to further...
Douglas Kim
Follow
307 Views
Share
bearish
•
LG Energy Solution
•
30 Jun 2022 18:31
End of Mandatory Lock-Up Periods for 40 Companies in Korea in July 2022
We discuss end of the mandatory lock-up periods for 40 stocks in Korea in July 2022.Among these 40 stocks, LG Energy Solution could face further...
Douglas Kim
Follow
574 Views
Share
Previous
1
2
3
Next
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.5
x